You are here

CAR-T

Anixa Hits FDA Speedbump for Ovarian Cancer CAR-T Trial Approval

Anixa Hits FDA Speedbump for Ovarian Cancer CAR-T Trial Approval

BioSpace

Anixa Biosciences

Flag link:

AACR attendees told about tactics to tackle loss of T cell function in CAR T cell treatment

AACR attendees told about tactics to tackle loss of T cell function in CAR T cell treatment

Biopharma Reporter

Memorial Sloan Kettering

Flag link:

Precision reacquires rights to allogeneic CAR-Ts from Servier

Precision reacquires rights to allogeneic CAR-Ts from Servier

Fierce Biotech

Precision Biosciences

allogeneic cells

Flag link:

Bluebird, PsiOxus show oncolytic virus boosts CAR-T in solid tumors

Bluebird, PsiOxus show oncolytic virus boosts CAR-T in solid tumors

Fierce Biotech

Flag link:

5 takeaways from AACR, one of the year's top meetings on cancer drugs

5 takeaways from AACR, one of the year's top meetings on cancer drugs

BioPharma Dive

Bristol Myers Squibb

Flag link:

Sanofi spends $160M in bet that Tidal’s tech gets it to off-the-shelf CAR-T therapy

Sanofi spends $160M in bet that Tidal’s tech gets it to off-the-shelf CAR-T therapy

MedCity News

Tidal Therapeutics

Flag link:

Kite: New data offers transparency into CAR T cell therapy manufacturing in real world setting

Kite: New data offers transparency into CAR T cell therapy manufacturing in real world setting

Biopharma Reporter

Flag link:

New CAR-T therapy from Bristol, Bluebird effective but too costly, ICER finds

New CAR-T therapy from Bristol, Bluebird effective but too costly, ICER finds

BioPharma Dive

Bristol Myers Squibb

Multiple Myeloma

Flag link:

Bristol Myers, bluebird bio have their BCMA CAR-T nod, but latecomer J&J could have an advantage: analysts

Bristol Myers, bluebird bio have their BCMA CAR-T nod, but latecomer J&J could have an advantage: analysts

Fierce Pharma

Bristol Myers Squibb

Flag link:

FDA approves first CAR-T cell therapy for multiple myeloma

FDA approves first CAR-T cell therapy for multiple myeloma

BioPharma Dive

Bristol-Myers Squibb

Multiple Myeloma

Flag link:

Novartis exec says Kymriah's ready to square off with Bristol Myers' new CAR-T rival Breyanzi

Novartis exec says Kymriah's ready to square off with Bristol Myers' new CAR-T rival Breyanzi

Fierce Pharma

Bristol Myers Squibb

Flag link:

Bristol Myers scales up cell therapy production with liso-cel nod in hand and another approval maybe on the way

Bristol Myers scales up cell therapy production with liso-cel nod in hand and another approval maybe on the way

Endpoints

Bristol-Myers Squibb

drug manufacturing

Flag link:

Bristol Myers Takes $470 Million Write-off and Scraps Orva-Cel CAR-T Program

Bristol Myers Takes $470 Million Write-off and Scraps Orva-Cel CAR-T Program

BioSpace

Bristol-Myers Squibb

Flag link:

Bristol Myers Squibb's CAR-T liso-cel wins long-delayed FDA nod

Bristol Myers Squibb's CAR-T liso-cel wins long-delayed FDA nod

Fierce Pharma

Bristol-Myers Squibb

Flag link:

New study points to why CAR-T therapy may fail in some lymphoma patients

New study points to why CAR-T therapy may fail in some lymphoma patients

Fierce Biotech

Flag link:

Janssen flags accelerated approval milestone in Europe for CAR-T therapy

Janssen flags accelerated approval milestone in Europe for CAR-T therapy

Biopharma Reporter

Flag link:

FDA blasts Lonza facility in Form 483 that derailed Bristol Myers' plan of liso-cel nod by 2020

FDA blasts Lonza facility in Form 483 that derailed Bristol Myers' plan of liso-cel nod by 2020

Fierce Pharma

Bristol-Myers Squibb

Flag link:

Bold Predictions for Medtech in 2021

Bold Predictions for Medtech in 2021

Medical Devices and Diagnostics Industry

remote patient monitoring

digital medicine

artificial intelligence

machine learning

robotic surgery

Flag link:

Factor Bioscience spins out a new cell therapy player with eyes on the clinic within 2 years

Factor Bioscience spins out a new cell therapy player with eyes on the clinic within 2 years

Endpoints

Factor Bioscience

Flag link:

Autolus buckles down, chopping 20% of staff and seeking partner for a lead CAR-T program

Autolus buckles down, chopping 20% of staff and seeking partner for a lead CAR-T program

Endpoints

Autolus Therapeutics

diffuse large B-cell lymphoma

Flag link:

Pages